NCT01266954 2017-11-09An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian CancerGlaxoSmithKlinePhase 1 Completed36 enrolled